Novel Mn4+-Activated K2Nb1-xMoxF7 (0 ≤ x ≤ 0.15) Solid Solution Red Phosphors with Superior Moisture Resistance and Good Thermal Stability.

Nowadays, Mn4+-activated fluoride red phosphors with excellent luminescence properties have triggered tremendous attentions for enhancing the performance of white light-emitting diodes (WLEDs). Nonetheless, the poor moisture resistance of these phosphors impedes their commercialization. Herein, we proposed the dual strategies of "solid solution design" and "charge compensation" to design K2Nb1-xMoxF7 novel fluoride solid solution system, and synthesized the Mn4+-activated K2Nb1-xMoxF7 (0 ≤ x ≤ 0.15, x represents the mol % of Mo6+ in the initial solution) red phosphors via co-precipitation method. The doping of Mo6+ not only significantly improve the moisture resistance of the K2NbF7: Mn4+ phosphor without any passivation and surface coating, but also effectively enhance the luminescence properties and thermal stability. In particular, the obtained K2Nb1-xMoxF7: Mn4+ (x = 0.05) phosphor possesses the quantum yield of 47.22% and retains 69.95% of its initial emission intensity at 353 K. Notably, the normalized intensity of the red emission peak (627 nm) for the K2Nb1-xMoxF7: Mn4+ (x = 0.05) phosphor is 86.37% of its initial intensity after immersion for 1440 min, prominently higher than that of the K2NbF7: Mn4+ phosphor. Moreover, a high-performance WLED with high CRI of 88 and low CCT of 3979 K is fabricated by combining blue chip (InGaN), yellow phosphor (Y3Al5O12: Ce3+) and the K2Nb1-xMoxF7: Mn4+ (x = 0.05) red phosphor. Our findings convincingly demonstrate that the K2Nb1-xMoxF7: Mn4+ phosphors have a good practical application in WLEDs.

Proteomics-based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins.

Monoclonal antibodies (mAbs) have the potential to be a very powerful tool in proteomics research to determine protein expression, quantification, localization and modification, as well as protein-protein interactions, especially when combined with microarray technology. Thus, a large amount of well-characterized and highly qualified antibodies are needed in proteomics. Purified antigen, which is not always available, has proven to be one of the rate-limiting steps in mAb large-scale generation. Here we describe our strategies to establish a murine hybridoma cell bank for human liver mitochondria using unknown native proteins as the immunogens. The antibody-recognized mitochondrial proteins were identified by MS following immunoprecipitation (IP), and by screening of human liver cDNA expression library. We found that the established antibodies reacted specifically with a number of important enzymes in mitochondria. The subcellular localization of these antigens in mitochondria was further confirmed by immunohistocytochemistry. A panel of antibodies was also tested for their ability to capture and deplete the targeting proteins and complexes from the total mitochondrial proteins. We believe these well-characterized antibodies would be useful in various applications for Human Liver Proteome Project (HLPP) when the scale of this hybridoma cell bank is enlarged significantly in the near future.